New Phase I Breast Cancer Study Awarded in Russia
GCT has been awarded a new Phase I clinical trial in patients with breast cancer. It aims to prove the safety, tolerance and pharmacokinetics of the Investigated Medical Product (IMP) using the dose escalation method. The study will be conducted in Russia with enrolling 60 patients who suffer from palindromic or refractory metastatic breast cancer. The project is sponsored by a Russian biotechnology start-up company specializing in oncology research.
August 3, 2020
Chronic Pancreatitis Study: First Patient In
GCT is proud to announce successful enrollment of the first patient in Russia in the Chronic Pancreatitis clinical trial. The multinational Phase II randomized double-blind Gastroenterology trial is aiming to enroll over 160 patients in total. GCT is managing the study in Russia and Ukraine and covering the full-service clinical support.
July 15, 2020
GCT to Conduct a Rare Pulmonary Disease Study
GCT has been awarded a new clinical trial in Ukraine and Russia. A Phase II multinational study in subjects with Idiopathic Pulmonary Fibrosis (IPF) is designed to investigate the safety, efficacy, and pharmacokinetics of the investigational product.
July 7, 2020
Multinational Natural History Rare Disease Study Extension
GCT is awarded to run the rare disease project globally. The trial is already ongoing and managed by GCT in India. In addition to that, the sites will now open in Western and Mediterranean Europe, Western Asia, and Great Britain. GCT is providing regulatory, clinical trial management, EU Legal representation and GDPR support for this study.
The indication under research is an extremely rare genetic disease inherited as an autosomal recessive trait.
June 25, 2020
Meet our clients
All trademarks, brand names and logotypes are intellectual property of their respective owners.
Pennsylvania Convention Center
Philadelphia, PA, USA
2020, September 09—11